Optimal treatment sequencing in advanced prostate cancer

These hypothetical case studies are sponsored by Novartis. FA-11474311, FA-11474313, FA-11474314, FA-11474317.

Date of Preparation: July 2025.

All characters and events depicted in this patient case simulation are entirely fictitious. This activity is intended for a global audience of healthcare professionals.

The information presented is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of their professional license, experience, and knowledge of the individual patient.

This program offers clinicians the latest, evidence-based insights into the diagnosis and treatment of metastatic castration-resistant prostate cancer (mCRPC). With a focus on the latest standards of care, the content explores how to select, sequence, and individualize management strategies—based on Level 1 clinical evidence. Through expert-led case discussions the program empowers healthcare professionals to make informed decisions and optimize outcomes for patients with mCRPC.
Steering committee (all speaker images used in this material have been included with the express permission of the individuals featured.)
The case-based modules